InMode Ltd. (NASDAQ:INMD) Shares Acquired by Marathon Asset Management Ltd

Marathon Asset Management Ltd boosted its holdings in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 57.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 182,349 shares of the healthcare company's stock after purchasing an additional 66,475 shares during the quarter. Marathon Asset Management Ltd owned approximately 0.22% of InMode worth $3,045,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of INMD. Nisa Investment Advisors LLC lifted its position in shares of InMode by 314.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company's stock valued at $60,000 after buying an additional 2,694 shares in the last quarter. Quarry LP raised its position in InMode by 154.3% during the third quarter. Quarry LP now owns 3,781 shares of the healthcare company's stock worth $64,000 after acquiring an additional 2,294 shares during the period. SBI Securities Co. Ltd. purchased a new position in InMode during the fourth quarter valued at $87,000. National Bank of Canada FI lifted its holdings in InMode by 6.2% during the third quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company's stock valued at $169,000 after purchasing an additional 579 shares in the last quarter. Finally, DGS Capital Management LLC acquired a new stake in shares of InMode in the third quarter valued at about $182,000. 68.04% of the stock is owned by institutional investors and hedge funds.

InMode Price Performance

INMD traded up $0.05 on Thursday, reaching $19.31. 926,629 shares of the company's stock were exchanged, compared to its average volume of 928,732. InMode Ltd. has a twelve month low of $14.87 and a twelve month high of $23.38. The stock has a market cap of $1.34 billion, a PE ratio of 8.22 and a beta of 2.13. The stock's fifty day moving average price is $17.67 and its 200-day moving average price is $17.47.

Remove Ads

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Barclays lifted their price objective on InMode from $26.00 to $29.00 and gave the stock an "overweight" rating in a report on Wednesday, February 5th. Needham & Company LLC restated a "hold" rating on shares of InMode in a research report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $22.25.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.